TheraRadar
Data updated: May 26, 2026

READI-CAT 2 (barium sulfate)

X-Ray Contrast Activity
Other Approved 2016-01-15

Liquid E-Z-PAQUE is indicated for use in single contrast radiographic examinations of the esophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.

Source: FDA Label • BRACCO
7
Indications
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2016-01-15
Routes
ORAL
Dosage Forms
SUSPENSION

Companies

Active Ingredient: BARIUM SULFATE

READI-CAT 2 Approval History

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
9 FDA actions from 2016 to 2022 · 6 indication expansions
Mar 2022 SUPPL
Mfg · Manufacturing (CMC)
May 2020 SUPPL
Efficacy
Mar 2018 SUPPL
Efficacy

What READI-CAT 2 Treats

7 FDA approvals

Originally approved for its first indication in 2016 . Covers 7 distinct patient populations.

  • Other (7)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

READI-CAT 2 FDA Label Details

Indications & Usage

FDA Label (PDF)

Liquid E-Z-PAQUE is indicated for use in single contrast radiographic examinations of the esophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients. Liquid E-Z-PAQUE is a radiographic contrast agent indicated for use in single contrast radiographic examinations of the esophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients

Track READI-CAT 2 with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.